PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.




PMID- 28739756
OWN - NLM
STAT- MEDLINE
DA  - 20170725
DCOM- 20170803
LR  - 20170803
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 37
IP  - 8
DP  - 2017 Aug
TI  - Better Clinical Efficiency of TILs for Malignant Pleural Effusion and Ascites
      than Cisplatin Through Intrapleural and Intraperitoneal Infusion.
PG  - 4587-4591
AB  - BACKGROUND/AIM: To evaluate the clinical efficiency of tumor-infiltrating
      lymphocytes (TILs) compared to cisplatin for malignant pleural effusion and
      ascites through intrapleural and intraperitoneal infusion. PATIENTS AND METHODS: 
      Thirteen patients with malignant pleural effusion and ascites were divided into a
      TIL-treated group and a cisplatin-treated group. Patients were given TILs or
      cisplatin, through intrapleural and intraperitoneal infusion respectively, after 
      drainage of the malignant serous effusion by thoracentesis or abdominocentesis.
      RESULTS: The overall response rate and disease control rate of the TIL-treated
      group (33.33% and 83.33%) were higher than that of the cisplatin-treated group
      (28.57% and 71.43%). The progression-free survival for the TIL-treated group was 
      significantly longer (p=0.002) and better than that of the cisplatin-treated
      group (66.67% vs. 28.57%). Quality of life apparently improved in the TIL-treated
      group and was clearly higher than that in the cisplatin-treated group.
      CONCLUSION: The use of TILs has a better clinical efficiency for malignant
      pleural effusion and ascites than cisplatin through intrapleural and
      intraperitoneal infusion without severe adverse effects.
CI  - Copyright(c) 2017, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Chu, Hongjin
AU  - Chu H
AD  - The Central Laboratory, The Affiliated Yantai Yuhuangding Hospital of Qingdao
      University, Yantai, P.R. China.
FAU - DU, Fengcai
AU  - DU F
AD  - The First Clinical College of DaLian Medical University, Dalian, P.R. China.
FAU - Gong, Zhaohua
AU  - Gong Z
AD  - Department of Oncology, The Affiliated Yantai Yuhuangding Hospital of Qingdao
      University, Yantai, P.R. China.
FAU - Lian, Peiwen
AU  - Lian P
AD  - The Central Laboratory, The Affiliated Yantai Yuhuangding Hospital of Qingdao
      University, Yantai, P.R. China.
FAU - Wang, Zhixin
AU  - Wang Z
AD  - The Central Laboratory, The Affiliated Yantai Yuhuangding Hospital of Qingdao
      University, Yantai, P.R. China.
FAU - Li, Peng
AU  - Li P
AD  - Department of Oncology, The Affiliated Yantai Yuhuangding Hospital of Qingdao
      University, Yantai, P.R. China.
FAU - Hu, Baohong
AU  - Hu B
AD  - Department of Oncology, The Affiliated Yantai Yuhuangding Hospital of Qingdao
      University, Yantai, P.R. China.
FAU - Chi, Cheng
AU  - Chi C
AD  - The First Clinical College of DaLian Medical University, Dalian, P.R. China.
FAU - Chen, Jian
AU  - Chen J
AD  - The Central Laboratory, The Affiliated Yantai Yuhuangding Hospital of Qingdao
      University, Yantai, P.R. China [email protected]
AD  - Department of Oncology, The Affiliated Yantai Yuhuangding Hospital of Qingdao
      University, Yantai, P.R. China.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Biomarkers, Tumor)
RN  - Q20Q21Q62J (Cisplatin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Agents/*administration & dosage/adverse effects
MH  - Ascites/diagnosis/mortality/*therapy
MH  - Biomarkers, Tumor
MH  - Cisplatin/*administration & dosage/adverse effects
MH  - Female
MH  - Humans
MH  - *Immunotherapy, Adoptive/adverse effects/methods
MH  - Infusions, Parenteral
MH  - Lymphocytes, Tumor-Infiltrating/immunology/metabolism/*transplantation
MH  - Male
MH  - Middle Aged
MH  - Pleural Effusion, Malignant/diagnosis/mortality/*therapy
MH  - Quality of Life
MH  - Survival Analysis
MH  - Treatment Outcome
OTO - NOTNLM
OT  - TIL
OT  - Tumor-infiltrating lymphocytes
OT  - ascites
OT  - cisplatin
OT  - malignant pleural effusion
EDAT- 2017/07/26 06:00
MHDA- 2017/08/05 06:00
CRDT- 2017/07/26 06:00
PHST- 2017/05/19 [received]
PHST- 2017/06/15 [revised]
PHST- 2017/06/16 [accepted]
AID - 37/8/4587 [pii]
PST - ppublish
SO  - Anticancer Res. 2017 Aug;37(8):4587-4591.